- Home
- AVIR vs SCPH Comparison
AVIR vs SCPH Comparison
Compare AVIR & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- SCPH
- Stock Information
- Founded
- AVIR 2012
- SCPH 2013
- Country
- AVIR United States
- SCPH United States
- Employees
- AVIR N/A
- SCPH N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- AVIR Health Care
- SCPH Health Care
- Exchange
- AVIR Nasdaq
- SCPH Nasdaq
- Market Cap
- AVIR 290.4M
- SCPH 299.0M
- IPO Year
- AVIR 2020
- SCPH 2017
- Fundamental
- Price
- AVIR $2.91
- SCPH $5.63
- Analyst Decision
- AVIR Hold
- SCPH Buy
- Analyst Count
- AVIR 1
- SCPH 3
- Target Price
- AVIR $6.00
- SCPH $12.00
- AVG Volume (30 Days)
- AVIR 217.7K
- SCPH 2.4M
- Earning Date
- AVIR 11-06-2025
- SCPH 11-12-2025
- Dividend Yield
- AVIR N/A
- SCPH N/A
- EPS Growth
- AVIR N/A
- SCPH N/A
- EPS
- AVIR N/A
- SCPH N/A
- Revenue
- AVIR N/A
- SCPH $49,969,000.00
- Revenue This Year
- AVIR N/A
- SCPH $104.30
- Revenue Next Year
- AVIR N/A
- SCPH $76.06
- P/E Ratio
- AVIR N/A
- SCPH N/A
- Revenue Growth
- AVIR N/A
- SCPH 107.79
- 52 Week Low
- AVIR $2.46
- SCPH $1.94
- 52 Week High
- AVIR $4.15
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- AVIR 29.44
- SCPH 63.97
- Support Level
- AVIR $3.10
- SCPH $4.33
- Resistance Level
- AVIR $3.33
- SCPH $5.62
- Average True Range (ATR)
- AVIR 0.14
- SCPH 0.04
- MACD
- AVIR -0.05
- SCPH -0.01
- Stochastic Oscillator
- AVIR 7.69
- SCPH 86.67
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.